Medical condition
Rare Disease
Rare Disease is a medical condition tracked by NovaPharmaNews. Browse the latest pharmaceutical industry coverage and developments.
Latest Rare Disease news
Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
Only about 5% of rare diseases have an FDA-approved drug, but gene therapies are gaining ground. This analysis covers the latest FDA approved gene therapy list, including the recent approval of Kresladi for LAD-I, and what it means for pharma teams and investors.
BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
BioMarin Pharmaceutical's rare disease therapy failed to show clinical benefit in a Phase 3 trial, triggering a reassessment of R&D strategy and investor confidence. This article covers key takeaways, regulatory implications, and actionable insights for pharma business development and regulatory teams.
Palvella Secures $230M to Advance QTORIN for Rare Diseases
Palvella Therapeutics has raised $230 million to support the NDA for QTORIN, targeting rare diseases. This funding positions the company for significant growth.
Impact of FDA Turnover on Rare Disease Drug Development
Biotech executives and academic experts discuss the implications of FDA turnover on rare disease drug development, highlighting investment risks and opportunities.
BioMarin's SWOT Analysis: Competitive Headwinds in Rare Disease Biotech
This article provides a comprehensive SWOT analysis of BioMarin Pharmaceutical, focusing on its position in the rare disease biotech sector and the competitive landscape it faces.
BioMarin Drug Acquisition: Missed Goals in Rare Disease Study
BioMarin's recent drug study results raise questions about future strategies in rare disease treatment and investment implications.
AI Revolutionizes Treatment for Newborn's Ultra Rare Disease
This article explores the transformative role of AI in treating a newborn's ultra rare disease, highlighting its implications for the pharmaceutical industry.
Palvella's Nasdaq Uplisting: Implications for Rare Disease Development
Palvella Therapeutics has achieved a significant milestone by earning a spot on a stricter Nasdaq tier, signaling growth potential in the rare disease sector. This article analyzes the implications for investors and pharma teams.